본문으로 건너뛰기
← 뒤로

The membrane-associated ubiquitin ligase MARCHF8 degrades MHC-I in HPV-positive head and neck cancer for immune evasion.

Proceedings of the National Academy of Sciences of the United States of America 2026 Vol.123(11) p. e2525730123

Khalil MI, Wang J, Vu L, Yang C, Yin C, Chadha S, Nabors H, Vocelle D, May DG, Chrisopulos RJ, Welbon CC, Zhou L, Roux KJ, Spanos WC, Bernard MP, Mi QS, Pyeon D

📝 환자 설명용 한 줄

The loss of major histocompatibility complex class I (MHC-I) molecules has been proposed as a mechanism for cancer immune evasion.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Khalil MI, Wang J, et al. (2026). The membrane-associated ubiquitin ligase MARCHF8 degrades MHC-I in HPV-positive head and neck cancer for immune evasion.. Proceedings of the National Academy of Sciences of the United States of America, 123(11), e2525730123. https://doi.org/10.1073/pnas.2525730123
MLA Khalil MI, et al.. "The membrane-associated ubiquitin ligase MARCHF8 degrades MHC-I in HPV-positive head and neck cancer for immune evasion.." Proceedings of the National Academy of Sciences of the United States of America, vol. 123, no. 11, 2026, pp. e2525730123.
PMID 41802050

Abstract

The loss of major histocompatibility complex class I (MHC-I) molecules has been proposed as a mechanism for cancer immune evasion. Nevertheless, the mechanism is poorly understood. We report here that membrane-associated RING-CH-type finger 8 (MARCHF8), upregulated by human papillomavirus (HPV), ubiquitinates and degrades MHC-I in HPV-positive head and neck cancer (HPV+ HNC). Inhibiting MARCHF8 restores MHC-I levels on HPV+ HNC cells, suppresses tumor growth, and increases the infiltration of natural killer (NK) and T cells in the tumor microenvironment. Furthermore, knockout markedly increases cross talk between cytotoxic NK cells and CD8 T cells with macrophages and enhances the tumor-killing activity of CD8 T cells. Interestingly, knockout, in combination with anti-PD-1 treatment, further enhances tumor suppression and increases NK and T cell infiltration in mice bearing immune checkpoint inhibitor-refractory tumors. Our findings suggest that MARCHF8 could be a promising target for immunotherapy for HPV+ HNC patients.

MeSH Terms

Humans; Animals; Ubiquitin-Protein Ligases; Mice; Histocompatibility Antigens Class I; Head and Neck Neoplasms; Killer Cells, Natural; CD8-Positive T-Lymphocytes; Papillomavirus Infections; Tumor Microenvironment; Cell Line, Tumor; Immune Evasion; Membrane Proteins; Papillomaviridae; Tumor Escape